Rocket Pharmaceuticals, Inc. RCKT
2.36 USD -0.25 (-9.77%)
Nov 5, 2026, 11:16 AM EST
2.30 Day range 2.58
2.17 52-week range 5.45
- YTD
- -32.91%
- 1 year
- -29.07%
News
businesswire.com Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening…
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.
benzinga.com Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4 Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.
benzinga.com Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4 Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.
proactiveinvestors.com Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility Rocket Pharmaceuticals (NASDAQ: RCKT) shares rose 4% on Wednesday after the biotechnology company secured access to up to $150 million under a credit facility with Hercules Capital. The facility…- benzinga.com Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and…
businesswire.com Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening…- benzinga.com Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
defenseworld.net Rocket Pharmaceuticals (NASDAQ:RCKT) Given “Buy” Rating at Chardan Capital Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report)'s stock had its "buy" rating reissued by Chardan Capital in a report issued on Wednesday, Benzinga reports. They currently have a $11.00 target…
defenseworld.net Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset Rocket Pharmaceuticals (NASDAQ: RCKT) outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings,…
seekingalpha.com Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
marketbeat.com Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset Rocket Pharmaceuticals NASDAQ: RCKT outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings,…
businesswire.com Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening…
benzinga.com This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
zacks.com RCKT Aligns With FDA on Completing Phase II Study in Danon Disease Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
benzinga.com This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.- benzinga.com Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
247wallst.com Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More As the Federal Reserve prepares to move on rates and oil prices surge past $105, Wednesday's top analyst calls reveal which travel giants, homebuilders, and financial stocks Wall Street is quietly…
benzinga.com Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.
seekingalpha.com Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
gurufocus.com Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease [url="]Rocket Pharmaceuticals, Inc.[/url] (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and li
benzinga.com Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited…
businesswire.com Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening…
zacks.com Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
businesswire.com Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases,…
defenseworld.net Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of “Hold” by Analysts Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has received a consensus rating of "Hold" from the ten analysts that are covering the firm, Marketbeat Ratings reports. Three analysts…
zacks.com Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
benzinga.com Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15 Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.- benzinga.com Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over…
businesswire.com Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases,…
benzinga.com Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the first three patients treated in its global, pivotal Phase 2 trial for Danon disease.
benzinga.com Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.
benzinga.com Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observedRocket is actively engaging with the FDA to align on the path to pivotal trial…
benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I…- benzinga.com Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of…
benzinga.com Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings- benzinga.com B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9 B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $8 to $9.
benzinga.com Why Is Rocket Pharma Stock Soaring Friday? Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash runway and support growth plans.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com The FDA Approves Rocket Pharmaceuticals' Kresladi For Pediatric Patients With Severe Leukocyte Adhesion Deficiency-I First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by…
- benzinga.com Rocket Pharmaceuticals Enters Sales Agreement With Cantor Fitzgerald & Co. For ATM Offering Up To $100M https://www.sec.gov/Archives/edgar/data/1281895/000114036126008849/ny20066752x3_424b5.htm
- benzinga.com Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3 Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
benzinga.com Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10 Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.- benzinga.com Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.04 percent. This is a 38.71 percent increase over losses…
benzinga.com B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $8 B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $10 to $8.
benzinga.com Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
benzinga.com FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by March 2026.